502 related articles for article (PubMed ID: 28910970)
21. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
22. Omalizumab in the Therapy of Pediatric Asthma.
Poddighe D; Brambilla I; Licari A; Marseglia GL
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):103-109. PubMed ID: 29714140
[TBL] [Abstract][Full Text] [Related]
23. Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report.
Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
Can Respir J; 2019; 2019():8607657. PubMed ID: 31885750
[TBL] [Abstract][Full Text] [Related]
24. Novel Biological Therapies in Severe Asthma: Targeting the Right Trait.
Varricchi G; Marone G; Spadaro G; Russo M; Granata F; Genovese A; Marone G
Curr Med Chem; 2019; 26(16):2801-2822. PubMed ID: 29318959
[TBL] [Abstract][Full Text] [Related]
25. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
26. Childhood asthma as an allergic disease: rationale for the development of future treatment.
Tang ML; Powell CV
Eur J Pediatr; 2001 Dec; 160(12):696-704. PubMed ID: 11795676
[TBL] [Abstract][Full Text] [Related]
27. Biological therapies for eosinophilic asthma.
Patel SS; Casale TB; Cardet JC
Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
[TBL] [Abstract][Full Text] [Related]
28. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
[TBL] [Abstract][Full Text] [Related]
29. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
[TBL] [Abstract][Full Text] [Related]
31. Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies.
Wright LS; Phipatanakul W
Ann Allergy Asthma Immunol; 2016 Jul; 117(1):17-20. PubMed ID: 27371967
[No Abstract] [Full Text] [Related]
32. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
Adv Med Sci; 2011; 56(2):318-22. PubMed ID: 21940268
[TBL] [Abstract][Full Text] [Related]
33. Omalizumab therapy for children and adolescents with severe allergic asthma.
Romano C
Expert Rev Clin Immunol; 2015; 11(12):1309-19. PubMed ID: 26312385
[TBL] [Abstract][Full Text] [Related]
34. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
35. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
[TBL] [Abstract][Full Text] [Related]
36. [Biologicals in the Treatment of Bronchial Asthma].
Haasler I; Taube C
Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
[TBL] [Abstract][Full Text] [Related]
37. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
38. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effects of anti-immunoglobulin E antibodies on airway remodeling in a murine model of chronic asthma.
Kang JY; Kim JW; Kim JS; Kim SJ; Lee SH; Kwon SS; Kim YK; Moon HS; Song JS; Park SH; Lee SY
J Asthma; 2010 May; 47(4):374-80. PubMed ID: 20528589
[TBL] [Abstract][Full Text] [Related]
40. Severe asthma: When to resort to biological agents.
Tenero L; Rossignoli S; Piacentini G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]